Neuronetics Opens Greenbrook Mental Wellness Centers National Center of Excellence in Rockville, Maryland

Neuronetics announces the grand opening of a National Center of Excellence in Rockville, Maryland, for advanced mental health treatments.

Quiver AI Summary

Neuronetics, Inc. has announced the grand opening of the Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland, which is the largest facility in the Greenbrook network. This nearly 7,000-square-foot center aims to enhance patient-centered mental health care by expanding access to advanced treatment options like NeuroStar® TMS and SPRAVATO® for patients with depression and other psychiatric conditions that are challenging to treat. Dr. Geoffrey Grammer, the Chief Medical Officer, will oversee the center, which will also serve as a hub for clinical innovation and research in interventional psychiatry. The facility is designed to support high-volume operations for TMS therapy and is REMS-certified to ensure compliance for advanced treatments. The opening event will feature facility tours and a ribbon-cutting ceremony, signaling Neuronetics' commitment to improving outcomes in mental health care through innovative and effective treatment modalities.

Potential Positives

Neuronetics has opened a new National Center of Excellence for Greenbrook Mental Wellness Centers in Rockville, Maryland, marking a significant expansion of its interventional psychiatry operations.
The new facility is designed to improve access to advanced treatment options for patients with treatment-resistant depression and other psychiatric conditions, highlighting the company's commitment to enhancing patient care and outcomes.
This center will serve as a pilot site for evaluating emerging treatment modalities, positioning Neuronetics at the forefront of clinical innovation in mental health care.
With the introduction of advanced therapies like NeuroStar TMS and SPRAVATO, the facility reinforces Neuronetics' leadership role in non-drug, noninvasive treatments for major depressive disorder and other related conditions.

Potential Negatives

The press release emphasizes the need for effective in-office treatment solutions for patients with conditions inadequately treated with first-line therapies, highlighting a potentially significant gap in existing offerings that the company must address.
The mention of the incorporation of emerging psychedelic-class therapies indicates potential regulatory hurdles and uncertainties that could impact the implementation timeline and acceptance in the medical community.

FAQ

What is the new Greenbrook Center of Excellence in Rockville?

The Greenbrook Center of Excellence is a 7,000-square-foot facility focused on advanced interventional psychiatry, serving as a national model for mental health care.

Who oversees the Rockville Center of Excellence?

The Rockville Center of Excellence is overseen by Dr. Geoffrey Grammer, Chief Medical Officer of Neuronetics and Greenbrook.

What treatments are offered at the Rockville Center?

The facility offers NeuroStar TMS therapy and SPRAVATO® (esketamine) Nasal Spray for treatment-resistant depression and major depressive disorder.

How does the Rockville Center aim to improve mental health care?

The center focuses on expanding access to advanced treatments, driving clinical innovation, and enhancing patient-centered care in interventional psychiatry.

Where is the Rockville Center of Excellence located?

The Rockville Center is located at 15001 Shady Grove Road, Suite 220, Rockville, Maryland.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

EARLY ACCESS

Receive STIM Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$STIM Insider Trading Activity

$STIM insiders have traded $STIM stock on the open market 21 times in the past 6 months. Of those trades, 13 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $STIM stock by insiders over the last 6 months:

JOREY CHERNETT has made 13 purchases buying 3,603,314 shares for an estimated $4,766,008 and 0 sales.
KEITH J SULLIVAN has made 0 purchases and 3 sales selling 121,112 shares for an estimated $181,387.
WILLIAM ANDREW MACAN (EVP, CLO and CS) has made 0 purchases and 4 sales selling 34,219 shares for an estimated $50,962.
STEVEN PFANSTIEL (EVP, CFO and Treasurer) sold 16,431 shares for an estimated $22,017

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$STIM Revenue

$STIM had revenues of $34.5M in Q1 2026. This is an increase of 7.75% from the same period in the prior year.

You can track STIM financials on Quiver Quantitative's STIM stock page.

You can access data on STIM stock through the Quiver Quantitative API.

$STIM Hedge Fund Activity

We have seen 41 institutional investors add shares of $STIM stock to their portfolio, and 45 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JANE STREET GROUP, LLC removed 1,001,288 shares (-98.4%) from their portfolio in Q1 2026, for an estimated $1,451,867
RENAISSANCE TECHNOLOGIES LLC removed 474,900 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $688,605
ADVISORSHARES INVESTMENTS LLC added 346,277 shares (+127.8%) to their portfolio in Q1 2026, for an estimated $502,101
MARSHALL WACE, LLP removed 286,045 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $414,765
UBS GROUP AG added 263,551 shares (+10.1%) to their portfolio in Q1 2026, for an estimated $382,148
STATE STREET CORP added 258,380 shares (+44.2%) to their portfolio in Q1 2026, for an estimated $374,651
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 235,080 shares (-73.1%) from their portfolio in Q1 2026, for an estimated $340,866

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Full Release

MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar ^® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the grand opening of Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland. Overseen by Neuronetics’ Chief Medical Officer Geoffrey Grammer, M.D., the nearly 7,000-square-foot facility is the largest Greenbrook center to date and reflects a significant investment in the future of interventional psychiatry, serving as a national blueprint for advanced, patient-centered mental health care delivery.

Neuronetics is investing in the future of mental health care through a National Center of Excellence designed to expand access to advanced treatment options, accelerate clinical innovation, and improve patient outcomes. The new facility was intentionally designed to address the growing need for effective in-office treatment solutions for patients living with depression and other psychiatric conditions that are not adequately treated with first-line therapies.

“The Rockville Center of Excellence is more than a new facility; it is a blueprint for the future of interventional psychiatry,” said Cory Anderson, Executive Vice President and General Manager of Greenbrook Mental Wellness Centers. “By bringing together clinical innovation, advanced treatment options, and a patient-centered model of care, we are building a scalable approach to delivering interventional psychiatry and positioning Greenbrook to lead the field with the launch of innovative new treatment modalities.”

As the largest Greenbrook location, the flagship Rockville facility is designed to support high-volume NeuroStar TMS and SPRAVATO ^® operations and is REMS-certified, ensuring compliance and readiness for advanced treatment delivery. Geoffrey Grammer, M.D., Chief Medical Officer of Neuronetics and Greenbrook Mental Wellness Centers, provides clinical leadership for the Center of Excellence, drawing on his national expertise in interventional psychiatry and experience leading large multidisciplinary care teams. In addition to his executive responsibilities, Dr. Grammer maintains clinical hours at the center, where he provides direct patient care.

“Treatment-resistant depression remains one of the most urgent challenges in mental health care,” said Dr. Geoffrey Grammer. “The Rockville Center of Excellence will serve as Greenbrook’s National Center for Clinical Innovation and Research, providing the clinical infrastructure needed to expand access to advanced interventional treatments, evaluate emerging therapies, and continue improving patient-centered psychiatric care.”

The Rockville location offers NeuroStar Advanced Therapy, the leading TMS treatment for major depressive disorder (MDD) in adults and adolescents aged 15 and older, backed by the largest clinical data set of any TMS treatment system for depression. NeuroStar is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder (OCD). The center also offers SPRAVATO (esketamine) Nasal Spray for patients with treatment-resistant depression or MDD with suicidal ideation. As Greenbrook's National Center for Clinical Innovation and Research, the facility will serve as a pilot site for emerging treatment modalities before broader implementation across the network. Its specialized clinical infrastructure also positions Greenbrook to evaluate and, if approved by the U.S. Food and Drug Administration, incorporate emerging psychedelic-class therapies into its model of care.

Greenbrook Mental Wellness Centers will host a grand opening celebration for the Rockville Center of Excellence, located at 15001 Shady Grove Road, Suite 220, Rockville, Maryland, featuring a ribbon-cutting ceremony and facility tours. To refer a patient, learn more about treatment options, or find a Greenbrook location near you, please visit GreenbrookTMS.com . For more information about NeuroStar TMS Therapy, please visit NeuroStar.com .

About Neuronetics
Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar ^® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO ^® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO ^® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant. ¹

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com .

Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
[email protected]

Media:
EvolveMKD
646.517.4220
[email protected]

###

References
¹ The effectiveness of SPRAVATO ^® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO ^® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO ^® . For more important safety information about SPRAVATO ^® , please visit spravatohcp.com .